Abstract
The accumulation of misfolded or unfolded proteins in endoplasmic reticulum (ER) lumen results in the activation of an adaptive stress process called the unfolded protein response (UPR). As the most conserved signaling branch of the UPR, Inositol-requiring enzyme 1 (IRE1) possesses both Ser/Thr kinase and RNase activities operating as major stress sensors, mediating both adaptive and pro-apoptotic pathways under ER stress. Over the last three decades, a mounting body of evidence has shown that IRE1 signaling dysfunction is involved in the pathology of various neurological disorders. Targeting this pathway has emerged as a promising therapeutic strategy against these diseases. In this review, we provide a general overview about the expression and physiological function of IRE1 signaling and its pathophysiological roles in the central nervous system diseases.
Keywords: Inositol-requiring enzyme 1, X box-binding protein 1, diseases, central nervous system, Alzheimer`s disease, Parkinson`s disease, ischemic stroke.
Graphical Abstract
Current Neuropharmacology
Title:The Role of IRE1 Signaling in the Central Nervous System Diseases
Volume: 16 Issue: 9
Author(s): Haibo Ni, Qin Rui, Di Li*, Rong Gao and Gang Chen
Affiliation:
- Department of Translational Medicine Center, The First People`s Hospital of Zhangjiagang City, Suzhou, Jiangsu,China
Keywords: Inositol-requiring enzyme 1, X box-binding protein 1, diseases, central nervous system, Alzheimer`s disease, Parkinson`s disease, ischemic stroke.
Abstract: The accumulation of misfolded or unfolded proteins in endoplasmic reticulum (ER) lumen results in the activation of an adaptive stress process called the unfolded protein response (UPR). As the most conserved signaling branch of the UPR, Inositol-requiring enzyme 1 (IRE1) possesses both Ser/Thr kinase and RNase activities operating as major stress sensors, mediating both adaptive and pro-apoptotic pathways under ER stress. Over the last three decades, a mounting body of evidence has shown that IRE1 signaling dysfunction is involved in the pathology of various neurological disorders. Targeting this pathway has emerged as a promising therapeutic strategy against these diseases. In this review, we provide a general overview about the expression and physiological function of IRE1 signaling and its pathophysiological roles in the central nervous system diseases.
Export Options
About this article
Cite this article as:
Ni Haibo , Rui Qin , Li Di *, Gao Rong and Chen Gang, The Role of IRE1 Signaling in the Central Nervous System Diseases, Current Neuropharmacology 2018; 16 (9) . https://dx.doi.org/10.2174/1570159X16666180416094646
DOI https://dx.doi.org/10.2174/1570159X16666180416094646 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Vaccine Development for Group A Streptococcus Infections and Associated Diseases
Current Drug Targets Interaction Between KATP-Channels and Protein Kinase C in the Regulation of Basal Coronary Flow
Vascular Disease Prevention (Discontinued) Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science Pharmacokinetics of Selegiline in a Rabbit Model
Letters in Drug Design & Discovery Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
Current Drug Safety Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Hypertension in Older Patients
Current Hypertension Reviews CRF Receptor Antagonists: Utility in Research and Clinical Practice
Current Medicinal Chemistry Waste Material of Propolis as a Film Forming Agent Intended to Modify the Metronidazole Release: Preparation and Characterization
Current Drug Delivery Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension
CNS & Neurological Disorders - Drug Targets The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor α(PPARα) Agonists,PPARγ Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (HMG-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (ACE)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Prodrug Design Targeting Intestinal PepT1 for Improved Oral Absorption: Design and Performance
Current Drug Metabolism The Renin-Angiotensin System: The Role of Inhibitors, Blockers, and Genetic Polymorphisms in the Treatment and Prevention of Heart Failure
Current Vascular Pharmacology The Use of Thiazides in Chronic Kidney Disease
Current Hypertension Reviews Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews